fig1
Figure 1. AASLD practice guidance: Patient selection criteria for MASH-targeted treatment with semaglutide. Created in BioRender. com. AASLD: American Association for the Study of Liver Diseases; ELF: enhanced liver fibrosis; F2-F3: fibrosis stage 2-3; MASH: metabolic dysfunction-associated steatohepatitis; MASLD: metabolic dysfunction-associated steatotic liver disease; MRE: magnetic resonance elastography; NIT: non-invasive test; VCTE: vibration-controlled transient elastography; mg: milligram; kPa: kilopascal.
